182 related articles for article (PubMed ID: 34126793)
1. Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2
Santamaria S; Gagliani MC; Bellese G; Marconi S; Lechiara A; Dameri M; Aiello C; Tagliatti E; Castagnola P; Cortese K
J Histochem Cytochem; 2021 Jul; 69(7):461-473. PubMed ID: 34126793
[TBL] [Abstract][Full Text] [Related]
2. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
Drucker A; Yoo BH; Khan IA; Choi D; Montermini L; Liu X; Jovanovic S; Younis T; Rosen KV
Breast Cancer Res; 2020 Oct; 22(1):105. PubMed ID: 33023655
[TBL] [Abstract][Full Text] [Related]
4. Neratinib is a TFEB and TFE3 activator that potentiates autophagy and unbalances energy metabolism in ERBB2+ breast cancer cells.
Bellese G; Tagliatti E; Gagliani MC; Santamaria S; Arnaldi P; Falletta P; Rusmini P; Matteoli M; Castagnola P; Cortese K
Biochem Pharmacol; 2023 Jul; 213():115633. PubMed ID: 37269887
[TBL] [Abstract][Full Text] [Related]
5. A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
Bailey TA; Luan H; Tom E; Bielecki TA; Mohapatra B; Ahmad G; George M; Kelly DL; Natarajan A; Raja SM; Band V; Band H
J Biol Chem; 2014 Oct; 289(44):30443-30458. PubMed ID: 25225290
[TBL] [Abstract][Full Text] [Related]
6. Endocytic degradation of ErbB2 mediates the effectiveness of neratinib in the suppression of ErbB2-positive ovarian cancer.
Wang S; Zhang J; Wang T; Ren F; Liu X; Lu Y; Xu L; Zhang Y; Wang D; Xu L; Wu Y; Liu F; Li Q; Zaky MY; Liu S; Dong W; Liu F; Zou K; Zhang Y
Int J Biochem Cell Biol; 2019 Dec; 117():105640. PubMed ID: 31689531
[TBL] [Abstract][Full Text] [Related]
7. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
Barr DJ; Ostermeyer-Fay AG; Matundan RA; Brown DA
J Cell Sci; 2008 Oct; 121(Pt 19):3155-66. PubMed ID: 18765569
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2
Marconi S; Santamaria S; Bartolucci M; Stigliani S; Aiello C; Gagliani MC; Bellese G; Petretto A; Cortese K; Castagnola P
Membranes (Basel); 2021 Mar; 11(3):. PubMed ID: 33809102
[TBL] [Abstract][Full Text] [Related]
9. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
10. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.
Cortese K; Howes MT; Lundmark R; Tagliatti E; Bagnato P; Petrelli A; Bono M; McMahon HT; Parton RG; Tacchetti C
Mol Biol Cell; 2013 Jan; 24(2):129-44. PubMed ID: 23154999
[TBL] [Abstract][Full Text] [Related]
11. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation.
Dietrich M; Malik MS; Nikolaysen F; Skeie M; Stang E
Exp Cell Res; 2018 Oct; 371(1):139-150. PubMed ID: 30098331
[TBL] [Abstract][Full Text] [Related]
14. Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2.
Hashizume T; Fukuda T; Nagaoka T; Tada H; Yamada H; Watanabe K; Salomon DS; Seno M
Cell Biol Int; 2008 Jul; 32(7):814-26. PubMed ID: 18442934
[TBL] [Abstract][Full Text] [Related]
15. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis.
Costa Verdera H; Gitz-Francois JJ; Schiffelers RM; Vader P
J Control Release; 2017 Nov; 266():100-108. PubMed ID: 28919558
[TBL] [Abstract][Full Text] [Related]
16. Combined Blockade of Activating
Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
[TBL] [Abstract][Full Text] [Related]
17. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
[TBL] [Abstract][Full Text] [Related]
18. Autophagy Blockade Limits HER2+ Breast Cancer Tumorigenesis by Perturbing HER2 Trafficking and Promoting Release Via Small Extracellular Vesicles.
Hao M; Yeo SK; Turner K; Harold A; Yang Y; Zhang X; Guan JL
Dev Cell; 2021 Feb; 56(3):341-355.e5. PubMed ID: 33472043
[TBL] [Abstract][Full Text] [Related]
19. Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells.
Karakas B; Ozmay Y; Basaga H; Gul O; Kutuk O
Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1073-1087. PubMed ID: 29733883
[TBL] [Abstract][Full Text] [Related]
20. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
